Samrat Pharmachem (530125) Stock Overview
Engages in the manufacture and sale of pharmaceutical chemicals in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
530125 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read more
Samrat Pharmachem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹203.20 |
| 52 Week High | ₹425.00 |
| 52 Week Low | ₹195.10 |
| Beta | -0.51 |
| 1 Month Change | -10.96% |
| 3 Month Change | -17.87% |
| 1 Year Change | -42.35% |
| 3 Year Change | -58.31% |
| 5 Year Change | 42.55% |
| Change since IPO | 3,964.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 530125 | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -3.0% | -2.7% | -3.0% |
| 1Y | -42.3% | -0.9% | 7.8% |
Return vs Industry: 530125 underperformed the Indian Chemicals industry which returned -0.9% over the past year.
Return vs Market: 530125 underperformed the Indian Market which returned 7.8% over the past year.
Price Volatility
| 530125 volatility | |
|---|---|
| 530125 Average Weekly Movement | 6.2% |
| Chemicals Industry Average Movement | 5.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: 530125 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 530125's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 28 | Lalit Mehta | www.samratpharmachem.com |
Samrat Pharmachem Limited engages in the manufacture and sale of pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodine, iodine monochloride, iodoquinol, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate and iodide, potassium metaper iodate, povidone iodine, sodium iodate and iodide, and sodium metaper iodate. The company serves the agrochemical, animal feed, chemical, cosmetics, food, pharmaceutical, printing, and textile industries.
Samrat Pharmachem Limited Fundamentals Summary
| 530125 fundamental statistics | |
|---|---|
| Market cap | ₹627.83m |
| Earnings (TTM) | -₹16.75m |
| Revenue (TTM) | ₹2.89b |
Is 530125 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 530125 income statement (TTM) | |
|---|---|
| Revenue | ₹2.89b |
| Cost of Revenue | ₹2.81b |
| Gross Profit | ₹81.14m |
| Other Expenses | ₹97.89m |
| Earnings | -₹16.75m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.42 |
| Gross Margin | 2.81% |
| Net Profit Margin | -0.58% |
| Debt/Equity Ratio | 15.5% |
How did 530125 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/08 04:45 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Samrat Pharmachem Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.